The products are listed under FDA product code HCC as Class II 510(k)-exempt biofeedback medical devices within the Neurology regulatory area. FDA establishment registration and device listing do not constitute FDA approval, clearance or authorization of the establishment or the listed devices. The initiation of NeuroVibe’s device listing is an important step in Datasea’s international commercialization strategy,” said Zhixin Liu, Chief Executive Officer of Datasea. Differentiated Pathway: From Hardware Device to a Data- and Software-Enabled Brain Health Technology PlatformDatasea’s differentiated strength lies in its acoustic AI technology pathway. Company OutlookDatasea believes that Shuhai Jingwei’s initiation of NeuroVibe’s listing as Class II 510(k)-exempt biofeedback medical devices further strengthens the Company’s strategic positioning in acoustic intelligence, AI-driven health technology and non-invasive neurotechnology.